In contrast, we found that the sensitivity of three types of biochemical tumor markers associated with SCLC [progastrin-releasing peptide (ProGRP), neuron-specific enolase (NSE), and carcinoembryonic antigen (CEA)] tested before treatment was relatively lower. This evidence concerns the gene ENO2 and neoplasm.